Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download report

De-risking regulatory submissions with Sano

A unified evidence platform for registries, real-world data, and long-term follow-up

Regulatory expectations for genomic medicine and advanced therapeutics continue to rise. Sponsors are under increasing pressure to deliver long-term follow-up, real-world evidence, and traceable data that can withstand regulatory scrutiny.

This report explains how Sano supports sponsors across the regulatory evidence lifecycle, from early patient registries through post-approval follow-up, using a unified, patient-centric platform.

In this report, you'll learn:
✅ Where regulators are raising expectations around evidence
✅ How Sano enables regulatory-grade patient registries
✅ How Sano supports sustained engagement over time

Who this report is for:
➡️ Regulatory affairs and clinical development leaders
➡️ Gene therapy and advanced therapeutics teams
➡️ RWE, data, and evidence strategy teams

Download now to learn more.

reggroup